Jefferies analyst Farzin Haque initiated coverage of Vor Bio (VOR) with a Buy rating and $50 price target which represents 268% upside. The company pivoted to autoimmune diseases in June of 2025 by licensing telitacicept globally outside of China from RemeGen, the analyst tells investors in a research note. The firm believes telitacicept is “well validated” in China. Jefferies sees a “valuation disconnect” in Vor shares and expects “outsized moves” with the pivotal generalized myasthenia gravis data in the first half of 2027.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR:
- Vor Biopharma: Strategic Autoimmune Pivot and Telitacicept’s >$2B gMG/SjD Opportunity Underpins Buy Rating
- Vor Biopharma Announces $75 Million Private Placement Financing
- Vor Bio to sell 5.338M shares at $14.05 in private placement
- Vor Bio initiated with an Overweight at Wells Fargo
- VOR Earnings this Week: How Will it Perform?